Fig. 6: YL-109 alleviated cisplatin-induced AKI.

A Light microscopic analysis showed that YL-109 alleviated cisplatin-induced cellular shrinkage. TUNEL staining revealed that YL-109 mitigated cisplatin-induced DNA damage in BUMPT cells. H & E staining demonstrated that YL-109 attenuated cisplatin-induced morphological changes in mouse kidneys. B Western blot studies demonstrated the upregulation of CHIP by YL-109 in BUMPT cells. C Cisplatin-induced upregulation of cleaved caspase 3 and BAX and downregulation of BCL2 was attenuated by YL-109 treatment in BUMPT cells, as indicated by Western blot procedures. D MTT analysis showed that YL-109 treatment alleviated cisplatin-induced cell death in BUMPT cells. (n = 6 *P = 0.0002 vs. WT group.) E Quantification of TUNEL staining. F Western blotting studies showed that CHIP was upregulated in YL-109-treated kidneys. G YL-109 attenuated cisplatin-induced upregulation of cleaved caspase 3 and BAX and downregulation of BCL2 in kidneys, as indicated by Western blot procedures. H YL-109 alleviated cisplatin-induced increase in serum creatinine levels; (n = 5 *P < 0.0001 vs. WT group; *P = 0.0123 vs. YL-109 group; #P = 0.0017 vs. WT + CP group.) I YL-109 alleviated cisplatin-induced increase in serum BUN levels; (n = 5 *P < 0.0001 vs. WT group; *P < 0.0001 vs. YL-109 group; #P < 0.0001 vs. WT + CP group.) J qRT-RT studies showed that the increased KIM1 mRNA levels induced by cisplatin were partially reduced by YL-109; (n = 4 *P < 0.0001 vs. WT group; *P < 0.0001 vs. YL-109 group; #P = 0.0017 vs. WT + CP group.) K qRT-RT studies showed that the increased NGAL mRNA levels induced by cisplatin were partially reduced by YL-109; (n = 4 *P < 0.0001 vs. WT group; *P < 0.0001 vs. YL-109 group; #P < 0.0001 vs. WT + CP group.) WT: wide type, CON: control, CP: cisplatin. Scale bars: 100 μm, Error bars show SD.